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 INTRODUCTION
 With a prevalence of approximately 10–15%, irritable bowel syn-
drome (IBS) is one of the most common gastrointestinal (GI) 
disorders in the industrialized world ( 1 ). Th e high prevalence 
together with the reduced quality of life and associated co-mor-
bidities in patients suff ering from IBS put a signifi cant negative 
burden on both patients and society ( 2 ). IBS is a heterogeneous 
functional disorder and commonly subtyped according to the 
prevailing bowel habit into IBS with constipation (IBS-C), IBS 
with diarrhea (IBS-D), mixed IBS with both constipation and 
diarrhea and unsubtyped IBS with neither constipation nor diar-
rhea using the Rome III criteria ( 3 ).
 Although the etiology of IBS is incompletely understood, it 
is generally regarded as a multifactorial disorder involving the 
interplay of both host and environmental factors, including diet. 
Th e host factors include central factors, such as aberrant stress 
responses, psychiatric co-morbidity, and cognitive dysfunctions, 
whereas intestinal functions are also involved, e.g., dysmotility, 
visceral hypersensitivity, low-grade immune activation, altered 
barrier function, and the intestinal microbiota composition ( 4 ).
 During recent years, perturbations in the intestinal microbiota 
are increasingly being linked to the pathophysiology of IBS. Th e 
increased risk of new onset IBS aft er an episode of gastroenteritis ( 5 ) 
and the association with prior antibiotic use ( 6 ) support the impor-
tance of the intestinal microbiota in IBS. Numerous studies have 
demonstrated altered microbial profi les in (specifi c subgroups of) 
IBS patients compared with healthy individuals ( 7–11 ). Th e intesti-
nal microbiota strongly interacts with exogenous factors, in particu-
lar diet, which may also directly or indirectly provoke IBS symptoms.
 In this review, we describe the current evidence regarding the 
impact of diet and the intestinal microbiota and their (inter)rela-
tion on the pathophysiology of IBS.
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 THE IMPACT OF DIET ON THE INTESTINAL 
MICROBIOTA
 Th e fetal intestine is thought to be sterile, although some recent 
studies indicate that colonization may already start before deliv-
ery, by bacterial transmission through the placental barrier 
( 12,13 ). Th e colonization during and upon delivery involves a 
succession of microbial populations, a seemingly chaotic process 
strongly infl uenced by birth mode and infant feeding. Vaginally 
born infants are initially colonized by maternal fecal and vaginal 
microbes, such as  Bifi dobacterium ,  Bacteroides ,  Prevotella, and 
 Lactobacillus spp., whereas infants born by cesarean section are 
inoculated by typical skin bacteria and bacteria from the hospital’s 
environment ( 14,15 ).
 Th e strong impact of diet on the indigenous microbial commu-
nities can already be observed even before weaning. Compared 
with formula-fed infants, the microbiota of breastfed infants is 
less diverse and more dominated by  Bifi dobacterium spp. ( 16–18 ). 
Th is is generally attributed to unique bioactive compounds such as 
human milk oligosaccharides that serve as metabolic substrates for 
a limited number of microbes ( 19 ), although breast milk itself also 
harbors a transferrable microbiota ( 20 ). A rapid diversifi cation of 
the infants’ intestinal microbiota and shift  toward an adult-like 
microbiota occurs with the introduction of solid foods ( 21,22 ); yet, 
the maturation of the microbiota appears to continue in parallel 
to physiological development of, for example, the gastrointestinal 
tract and the central nervous system, throughout childhood and 
adolescence ( 23,24 ).
 Once established, the intestinal microbiota appears to be rela-
tively stable within individuals over time ( 25 ), whereas high vari-
ability between individuals is observed ( 26–29 ).
 Pronounced diff erences in the composition and functional 
capacity of the human microbiota between geographically distant 
populations point toward an important role of the diet in these 
inter-individual variations ( 26,30–32 ). Th e microbiota in non-
Western populations, consuming a diet high in plant-derived 
carbohydrates, has consistently been shown to be more diverse 
and enriched in  Prevotella spp. at the expense of  Bacteroides spp. 
as compared with Western populations consuming a diet high in 
animal protein, sugar, starch, and fat (reviewed in ( 33 )). It remains 
to be determined to what extent the microbiota composition is 
shaped by the diet, as the impact of genetics, ethnic, and cultural 
factors, such as hygiene and living conditions, cannot be ruled out 
in such studies comparing distinct populations.
 Nevertheless, habitual long-term dietary patterns have also 
been directly linked to intestinal microbial enterotypes. Especially, 
protein and animal fat intake has been associated with the  Bacte-
roides enterotype, whereas a high carbohydrate intake was associ-
ated with the  Prevotella enterotype ( 34 ). Th e eff ect of short-term 
dietary interventions on the microbiota composition appears to be 
only modest ( 34,35 ), unless the intervention comprises an extreme 
switch in diet ( 36–38 ). David  et al. ( 37 ) demonstrated that even 
within days aft er the transition to a diet entirely composed of ani-
mal or plant products, changes in microbial structure, metabolic 
activity, and gene expression can be observed. In subjects receiv-
ing the animal-based high fat and protein diet, the abundance of 
bile-tolerant bacteria ( Alistipes, Bilophila and  Bacteroides ) together 
with branched short-chain fatty acids indicative of amino-acid 
fermentation increased, whereas levels of bacteria metabolizing 
dietary plant polysaccharides ( Eubacterium rectale, Roseburia, 
Ruminococcus bromii ) decreased. In agreement, switching to a diet 
high in resistant starch has been shown to increase  Ruminococ-
cus bromii and  Eubacterium rectale related species ( 39 ), which are 
known for their saccharolytic properties. Altogether, these studies 
indicate that the intestinal microbial community structure as well 
as its function and metabolic output are infl uenced by our diet, 
especially in the case of clearly distinct dietary patterns.
 INFLUENCE OF DIET ON IBS
 Surveys on perceived food intolerance show that 64–89% of IBS 
patients report their symptoms to be triggered by meals or spe-
cifi c foods ( 40–42 ) Th e majority indicate that they limit or exclude 
certain foods without professional counseling ( 40,42 ), thereby 
increasing the risk of inadequate dietary intake. Monsbakken 
 et al. ( 40 ) found indications for inadequate dietary intake in 12% 
of IBS patients studied, whereas others found adequate or even 
increased intake of some nutrients ( 43–45 ). Overall, data on 
habitual dietary intake are limited and may depend on the study 
population included. Meal-related symptom aggravation is fur-
ther supported by studies showing a postprandial worsening of 
pain using symptom diaries for 6 weeks ( 46 ) or rectal barostat 
( 47,48 ).
 Foods oft en reported to provoke symptoms include wheat/
grains, vegetables, milk products, fatty foods, spicy foods, coff ee, 
and alcohol ( 40–42,49 ) and are especially reported to be associ-
ated with abdominal pain and gas problems ( 41,42 ). Overall, the 
percentage of responders on exclusion diets varies from 15 to 71% 
( 50 ), but it has to be noted that most studies suff er from major 
methodological limitations and only a minority of subjects was 
found to react positively to double-blind food challenges ( 51–53 ).
 Although placebo and possibly nocebo eff ects have to be consid-
ered in IBS, possible physiological mechanisms of (perceived) food 
intolerance include an exaggerated sensory and motor response 
and/or incomplete absorption, which may lead to symptoms in a 
susceptible host. High fat intake, for example, is associated with an 
exaggerated colonic motor response to eating and increased visceral 
sensitivity in IBS patients, whereas duodenal lipid infusions delay 
small intestinal transit. Randomized controlled trials adjusting fat 
intake are, however, limited ( 54 ). Poorly absorbed carbohydrates, 
like lactose, fructose, and galacto- or fructo-oligosaccharides 
(fructans), can result in luminal distension by osmotic eff ects and 
increased gas production due to microbial fermentation. Although 
this is a normal physiological phenomenon, it can result in symp-
toms in subjects with an altered microbiota, increased visceral 
sensitivity, and/or abnormal gas handling. A recent study by Yang 
 et al. ( 55 ) found increased mucosal mast cell numbers, serum 
tumor necrosis factor-α , rectal sensitivity, and anxiety in lactose 
intolerant IBS-D patients, supporting that neuro-immune modula-
tion of visceral function is a potential underlying mechanism. Per-
ceived intolerance to lactose, fructose, and fructans is frequently 
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reported and uncontrolled studies point to symptom improvement 
aft er removal of milk containing products or wheat from the diet 
( 42 ). However, these studies should be interpreted with caution 
because of a large placebo and nocebo response in IBS. Th e overall 
evidence for an increased incidence of lactose intolerance in IBS 
patients was found to be weak and to be moderate—weak for the 
benefi t of low lactose intake in these subjects ( 56 ).
 Evolving from previous studies on lactose and fructose intol-
erance, a more generalized approach of intolerance to poorly 
absorbed and rapidly fermented carbohydrates has been intro-
duced: FODMAPS, including fermentable oligo-, di- and mono-
saccharides and polyols. Both retrospective and prospective open 
studies have shown reduced symptoms aft er introduction of a low-
FODMAP diet in IBS patients with suspected or proven fructose 
or lactose malabsorption ( 57,58 ). Th ese fi ndings are confi rmed by 
randomized controlled trials, showing a signifi cant improvement 
of overall symptoms, abdominal pain and bloating, in patients 
with bloating and/or diarrhea ( 59 ) and in small ( n =  15–30 ) unse-
lected IBS patient groups ( 60,61 ). One study showed recurrence 
of symptoms on re-challenge with fructose and/or fructans ( 62 ). 
Involvement of gas production is supported by fi ndings that IBS 
patients produced more hydrogen relative to healthy controls and 
lacked an increased methane production on a high vs. low-FOD-
MAP diet ( 60 ). However, it should be noted that the long-term 
benefi t of a low-FODMAP approach in large (unselected) patient 
groups is unclear, especially considering its invasiveness, which 
requires strict guidance by a dietician, and the potential risks of, 
for example, reduced fi ber intake and changes in microbiota com-
position and activity ( 59,63 ). Furthermore, randomized controlled 
trials are needed to prove whether it is superior to other dietary 
interventions (e.g., lactose or fructose reduction) or general die-
tary advice (e.g., the NICE guidelines). Finally, the FODMAP lev-
els vary between studies, countries, and products, which should be 
taken into account when interpreting study results and consider-
ing low-FODMAP diets.
 Foods can also evoke symptom onset by immune activation or 
altered neuro-endocrine responses ( 42 ). Food allergy or intoler-
ance associated with IgE-mediated immune responses is uncom-
mon and evidence for IgG/IgG4-mediated hypersensitivity is 
inconclusive ( 42,64 ). However, in subsets of IBS patients, increased 
numbers of T-lymphocytes, mast cells, eosinophils, and/or enter-
oendocrine cells have been found ( 65–67 ), but their exact role in 
food intolerance and symptom generation is unclear.
 Interest in the role of gluten intolerance (and the possible ben-
efi t of gluten-free diets) is increasing. A systematic meta-analysis 
found a pooled prevalence for celiac disease up to 4% among 
IBS patients ( 68 ). Th e prevalence of non-celiac gluten sensitivity 
among unselected IBS patients is unknown and complicated by 
clear diagnostic criteria and overlap in symptoms. Although symp-
tom reduction aft er a gluten-free diet ( 69 ) and worsening of symp-
toms aft er a gluten challenge ( 70 ) have been reported, the recent 
study Biesiekierski  et al. ( 71 ) found no symptom induction by giv-
ing pure gluten to IBS patients following a gluten- and FODMAP-
free diet. Th ese fi ndings suggest that not gluten but fructans and/
or other components might contribute to symptoms in perceived 
“wheat” intolerance. Furthermore, Carroccio  et al. ( 72 ) showed 
that the majority of IBS patients diagnosed with wheat sensitivity 
had multiple food sensitivities.
 Dietary supplementation studies focus on probiotics, prebiotics, 
synbiotics, and fi ber intake. A recent meta-analysis on the use of 
probiotics shows signifi cant eff ects on subjective global symptom 
improvement, but study heterogeneity is statistically signifi cant 
and no conclusions can be drawn on which individual species or 
strains are most benefi cial ( 73 ). Studies on prebiotics and synbiot-
ics are limited and insuffi  cient to draw conclusions. Evidence for 
the benefi t of dietary fi ber was found for soluble fi ber intake only 
( 74 ), but it should be noted that overall study quality was moderate 
and more studies are needed on its eff ects in IBS subgroups.
 Although several food components are associated with symp-
tom generation, detailed analyses on the eff ect of food intake on 
symptom generation and underlying mechanisms are limited. In 
addition, many studies suff er from methodological limitations, in 
part inherent to the complexity of food research.
 MICROBIOTA ALTERATIONS IN IBS
 Following the fi rst comprehensive analysis reporting a distinctive 
intestinal microbiota composition in IBS patients ( 75 ), several 
studies have identifi ed diff erences between the microbiota of IBS 
patients, or subgroups thereof, and healthy controls (reviewed 
in ( 7 )). Recently, clinical guidance regarding the modulation of 
intestinal microbiota in IBS was provided by the Rome Team 
Working Group ( 76 ), which concluded that there is good evidence 
supporting the concept that the intestinal microbiota is perturbed 
in patients with IBS. However, despite a growing consensus 
regarding an association between the intestinal microbiota and 
IBS, results of current studies lack general consensus and a spe-
cifi c microbial signature in IBS remains elusive ( Figure 1 ). Lack 
of detailed phenotypic characterization of patients, small sam-
ple sizes, and the cross-sectional study designs (providing only a 
single snapshot of the microbiota composition) in the majority 
of studies may all contribute to the fact that the markers of the 
IBS microbiota reported in several studies (marked in bold on 
 Figure 1 ) are not reproducibly detected in all cohorts. Moreover, 
exogenous factors, including diet, are most oft en not taken into 
account, despite the demonstrated eff ect of diet on the microbiota 
and the potential alterations in diet associated with IBS. Finally, 
it is noteworthy that Jeff rey and colleagues identifi ed distinct 
subsets of IBS patients, not corresponding to the traditional IBS 
subtypes, with an altered or normal-like microbiota composition 
( 8 ), indicating that the disturbed microbiota might be relevant for 
the pathology of part of the IBS patients. Moreover, those with a 
normal-like microbiota had more adverse psychological factors, 
suggesting that central factors may predominate over microbio-
logical factors in some but not all IBS patients.
 Several recent comprehensive studies of the microbiota in IBS 
have reported an increase in the relative abundance of  Firmicutes , 
mainly  Clostridium cluster XIVa and  Ruminococcaceae , together 
with a reduction in the relative abundance of  Bacteroidetes 
( 7–9,77 ). Bifi dobacteria have been shown to be depleted in both 
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fecal and mucosal samples of IBS patients ( 9,78–81 ), which adds 
to the trend toward a modest benefi cial eff ect of  Bifi dobacterium 
supplementation, in terms of the improvement of global IBS 
symptoms and pain scores as reported in a meta-analysis of pro-
biotic trials.( 73 ) A lower diversity and a higher instability of the 
( Firmicutes fraction or function of the) microbiota in IBS patients 
relative to controls have been reported ( 82–85 ), although these 
fi ndings need confi rmation in studies with suffi  cient depth of the 
microbiota analysis.
 Most if not all studies that compare microbial profi les in IBS 
patients and healthy controls are associative and cannot distinguish 
cause from consequence. However, evidence of a potential causal 
role for the GI microbiota is supported by a fecal transplantation 
experiment in which visceral hypersensitivity, presumed to under-
pin abdominal pain in a subgroup of IBS patients, could be trans-
ferred via the microbiota of IBS patients to previously germ-free 
rats ( 86 ). Furthermore, germ-free mice colonized with the micro-
biota from IBS-D patients have been shown to exhibit a faster GI 
transit and impaired intestinal permeability as compared with mice 
gavaged with the microbiota from healthy humans ( 87 ). Th e mech-
anisms through which the microbiota exerts these eff ects are not 
fully understood, but the fact that supernatants from colon biopsies 
of IBS patients, with increased levels of histamine and proteases, 
excite human submucosal neurons could indicate a brain–gut axis 
connection ( 88 ). Furthermore, an increase in fecal serine proteases 
has been linked with symptom development in IBS patients ( 89,90 ). 
Although the origin of both histamine and proteases could be both 
human and microbial, it is noteworthy that some of the  Firmi-
cutes bacteria that were found to be increased in abundance in IBS 
patients ( 8,9 ) are known to secrete large amounts of extracellular 
proteases ( 91 ). Alternatively, the predominantly endogenous fecal 
proteases might not be degraded by microbes because of the accel-
erated transit (as seen in IBS-D patients) or because of the disturbed 
metabolic activity of the microbiota ( 92 ). Serine protease inhibitors, 
the antagonists of serine proteases, are produced by many bacteria, 
including bifi dobacteria ( 93 ), which may contribute to the possible 
benefi t of bifi dobacterial supplementation.
 Dysregulated intestinal immune function, chronic low-grade 
mucosal infl ammation, and increased mucosal permeability and 
barrier dysfunction have all been suggested as putative patho-
genic mechanisms in IBS, in which the intestinal microbiota 
might have a role (reviewed in ( 76,94 )). Moreover, the bidirec-
tional interactions between the intestines and the central nervous 
system, which have an important role in the pathogenesis of IBS, 
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 FODMAPS, indigestible carbohydrates, can be fermented by 
intestinal microbes, resulting in increased gas production and an 
osmotic eff ect that can provoke IBS symptoms in a sensitive host 
( 108 ), although similar changes may go unperceived in normal 
subjects ( 109 ). Carbohydrate utilizing GI bacteria such as  Dorea 
spp., major gas producing bacteria in the human intestine ( 110 ), 
were reported to be signifi cantly increased in abundance in IBS 
patients ( 9,11 ). Overproduction of gas, specifi cally hydrogen, has 
been associated with IBS symptoms ( 111 ), especially abdomi-
nal pain and fl atulence. In patients with IBS-D, whose colon was 
found to be less able to accommodate the increased intestinal vol-
ume ( 112 ), overproduction of gas could be a trigger for increased 
colonic wall tension. In general, hydrogen produced in the gut is 
most effi  ciently removed by the methanogenic archaea ( 113 ) that 
appear to be depleted in IBS-D patients ( 9,10 ) and increased in 
IBS with constipation patients (reviewed in ( 114 )) Although there 
is substantial evidence for implication of methane in IBS sympto-
mology, most data are based upon methane breath testing. Hence, 
future studies, especially those addressing the diet-microbiota 
connection in IBS, should quantify methanogens to provide more 
direct evidence.
 Alternative pathway for gas elimination is the conversion into 
acetate by acetogenic bacteria,  Blautia spp. ( 115 ).  Blautia spp. are 
highly prevalent and dominant intestinal bacteria, which have 
been found to be elevated in IBS patients ( 9,79 ). Intriguingly, the 
major fermentation end-product—acetate—has been reported as 
signifi cantly increased in IBS patients ( 116 ), although this was 
not confi rmed in another study ( 117 ). Th is may relate to the fact 
that most studies measure stool concentrations without taking the 
total stool volume into account, thereby potentially concealing 
overall increased acetate production as a result of dilution due to 
increased stool volume.
 SCFAs produced upon the microbial fermentation of undigested 
carbohydrates and reduced levels thereof may also contribute to 
symptom generation in IBS. SCFAs have some documented health 
benefi ts, in particular butyrate, which is an important energy source 
for colonocytes, and among others inhibits infl ammation and 
enhances barrier function ( 118 ). Moreover, intraluminal adminis-
tration of butyrate into the distal colon has been shown to decrease 
visceral sensitivity in healthy humans ( 119 ). However, excessive 
intake of fermentable carbohydrates and high SCFA levels can also 
increase the osmotic load and thereby lead to diarrhea ( 120 ).
 Data on SCFAs in IBS are limited and inconsistent, showing no 
alterations, increased or decreased levels of SCFAs relative to con-
trols ( 61,116,117,121 ). Furthermore, altered SCFAs profi les might 
merely refl ect diet rather than a feature of the condition. Given 
that the major products of FODMAPs fermentation are SCFAs, 
and that some major microbial SCFA-producers may be altered in 
IBS, the connection between FODMAPs, SCFAs, microbiota, and 
IBS symptoms calls for further elucidation.
 Few studies have examined the impact of dietary interventions, 
in particular FODMAP restriction, on the microbiota in IBS 
patients. A low-FODMAP diet has been linked to reduced bifi do-
bacterial counts ( 59 ), which seems a paradox given their potential 
health benefi t. A recent study reported a reduction in total bac-
have suggested to be modulated by the microbiota (reviewed in 
( 95 )). Yet, there is a lack of data on the exact mechanisms through 
which the host-microbiota interactions underlie pathophysiology 
and generate symptoms. Identifying these mechanisms is further 
complicated by the fact that the majority of GI microbes remain 
uncharacterized ( 96 ). Indeed, most putative microbial markers 
of IBS are among uncultured bacteria. For example, uncultured 
bacteria related to  Ruminococcus torques are signifi cantly enriched 
in IBS patients in several cohorts ( 9,11,75 ), and their abundance 
positively correlates with bowel symptoms ( 9,10,97 ). It is intrigu-
ing that this bacterial group has been shown to be suppressed 
following a multispecies probiotic treatment that alleviated 
IBS symptoms ( 98 ). Similarly, uncultured bacteria within the 
 Clostridiales order are reproducibly detected in signifi cantly 
depleted abundance in IBS ( 9,10 ) but also in ulcerative colitis ( 99 ). 
Focus on the function of these uncultured bacteria should be of 
major interest for future studies.
 MICROBIOTA–DIET INTERACTIONS IN IBS
 Intestinal microbes have an important role in the digestion of 
dietary components, resulting in metabolites that may directly or 
indirectly contribute to IBS symptoms ( Figure 2 ).
 Colonic fermentation of carbohydrates mainly results in short-
chain fatty acids (SCFAs, including acetate, propionate, and 
butyrate) and variable amounts of hydrogen and carbon dioxide. 
Several low-abundant microbial groups can subsequently dis-
pose the produced hydrogen into acetate, hydrogen sulfi de, and 
methane. Th e fermentation of protein residues, primarily in the 
distal colon, produces a variety of metabolites, including ammo-
nia, organic acids, heterocyclic amides, and phenolic and indolic 
compounds, that are toxic and detrimental to gut health ( 100 ). 
Moreover, fat and digested proteins increase the excretion of bile 
acids that are subject to extensive bacterial transformation in the 
intestinal tract. Th is could be of particular relevance as bile acids 
inhibit many bacteria and may modulate microbiota composition 
and also have the potential to aff ect major pathophysiological fac-
tors in IBS, including GI motility, secretion, and immune function 
( 101,102 ). Indeed, in a recent large-scale study, increased colonic 
bile acid exposure was demonstrated in a subset of, predominantly 
non-constipated, IBS patients correlating with diarrhea and accel-
erated colonic transit ( 101 ).
 An association between the intestinal microbiota and pro-
tein metabolism has been established by a signifi cant correlation 
between the abundance of several post-infectious (PI)-IBS micro-
bial markers and host amino-acid metabolism ( 10 ). Among harm-
ful products of protein fermentation ( 100,103 ), hydrogen sulfi de 
might be relevant for compromising intestinal health as it directly 
impairs epithelial metabolism ( 104 ) and acts as a gut–brain sign-
aling molecule ( 105 ). Hydrogen sulfi de can be converted to thio-
sulfate and further oxidized to tetrathionate during infl ammation. 
Th e latter supports the growth of  Salmonella ( 106 ) and other 
tetrathionate utilizing pathogens from the Gamma-Proteobacteria 
class ( 107 ), many of which have been associated with bowel symp-
toms of IBS patients ( 9,10,82 ).
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terial abundance following the introduction of a low-FODMAP 
diet, as well as a reduction in absolute counts but not relative 
abundance of specifi c bacterial groups, including bifi dobacte-
ria as compared with habitual diet ( 63 ). However, as compared 
with a diet high in FODMAP content, the low-FODMAP diet 
appeared to be associated with marked lower relative abundances 
of butyrate-producing bacteria and  A. muciniphila , and a signifi -
cantly higher abundance of  R. torques , adding more paradoxical 
data on the eff ects of low-FODMAP diet ( 63 ).
 Extensive analyses of microbiota composition, functionality, 
and fermentation products in relation to FODMAP restriction and 
symptom generation are currently, however, lacking.
 Th e direct impact of diet-microbiota interactions on IBS symp-
toms has been demonstrated in an elegant study on the impact 
of a diet rich in fermentable substrates. Th e introduction of this 
fl atulogenic diet signifi cantly increased the gas volume and 
the number of gas evacuations, as well as abdominal symptoms 
and digestive discomfort in both healthy subjects and fl atulent 
Diet
Gut microbiota activity
Gut-brain axis
Bloating, flatulence
(e.g., SCFAs, amino acids,
BAs, ethanol, H2S)
(e.g., SCFAs, BAs, H2S)
(e.g., metabolites of protein fer-
mentation, BAs, ethanol, H2S)
(e.g., osmotic load,   CH4, BAs)
• Carbohydrates
 (e.g., FODMAPs, starch)
• Degradation of undigested proteins and
 carbohydrates:
 Sugars, oligosaccharides, peptides amino
 acids
• Amino acid and monosaccharide fermentation:
 SCFAs, lactate, succinate, ethanol, H2,
 CO2, amines, NH3, phenols, indoles, thiols
• Hydrogen disposal:
 CH4, H2S, acetate
• Bile-acid transformation:
 Deconjugated BAs, secondary BAs
• Fat
• Protein
Barrier function
Immune modulation
Cell damage
Transit abnormalities
(gas, mainly H2)
 Figure 2 .  Non-exclusive listing of dietary metabolites that can be regulated by microbial activity and contribute to irritable bowel syndrome (IBS) symp-
toms. The impact of metabolites affecting different domains of intestinal health is depicted; however, it should be noted that the effects of some metabo-
lites depend on their concentration or further conversion. Note: for immune modulation and barrier function, metabolites with positive and negative effects 
are colored in green and red, respectively. SCFAs, short-chain fatty acids; BAs, bile acids.
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plex and variable between individuals, it is clear that defi ning the 
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